Supplementary Figure S2 from FDA Approval Summary: Enfortumab Vedotin Plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial CarcinomaWilliam F. Maguire,Daniel Lee,Chana Weinstock,Xin Gao,Catharine C. Bulik,Sundeep Agrawal,Elaine Chang,Salaheldin S. Hamed,Erik W. Bloomquist,Shenghui Tang,Richard Pazdur,Paul G. Kluetz,Laleh Amiri-Kordestani,Daniel L. Suzmancrossref（2024）引用 0|浏览22暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
